The SOPHiA DDM™ Platform used by IHG PAS to
advance its research of male infertility
BOSTON and ROLLE, Switzerland, Nov. 17,
2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company and a leader in data-driven
medicine, today announced that the Institute of Human
Genetics, Polish Academy of Sciences (IHG PAS), the leading center
for genetics research in Poland,
is now live on the SOPHiA DDM™ Platform. IHG PAS will use SOPHiA
GENETICS to advance its research into rare disorders, in particular
male fertility.
It is estimated that roughly one in six people worldwide will be
affected by infertility in their lifetime.1 As a staple
in the medical research community of Poland, IHG PAS specializes in a variety of
research areas, including reproductive biology. By using the SOPHiA
DDM™ Platform, the Department of Reproductive Biology and Stem
Cells at IHG PAS intends to further their research in the area of
male infertility, via next-generation sequencing (NGS) for genetic
assessment of infertility.
"The research we do at IHG PAS is used broadly throughout
Poland due to our deep-rooted
relationships with the surrounding medical community and our nearly
50-year history," said Marta
Olszewska, Assistant Professor, Head of the Research Team of
Sperm Genetics, IHG PAS. "With the implementation of the SOPHiA
DDM™ Platform, our team is now able to expedite their research
and provide our partners with accelerated findings that can
positively impact the comprehension of infertility."
IHG PAS will be using the SOPHiA DDM™ Whole Exome Solution
(WES), which is a next-generation sequencing (NGS)-based
application that provides a streamlined end-to-end workflow, from
sample to variant report, to accelerate research of inherited
diseases, including infertility. Using the SOPHiA DDM™ Platform,
IHG PAS will have analyzed results and streamlined insights in an
efficient timeframe.
"The advanced analytical analysis provided by the SOPHiA DDM™
Platform provides overnight analysis of WES and has the rich
knowledge base to help identify variants of interest associated
with rare diseases." said Kevin Puylaert, Managing Director, EMEA,
SOPHiA GENETICS. "In addition, the decentralized
nature of the SOPHiA DDM™ Platform creates a collective
intelligence from all of the platform's users around the world can
help better inform researchers studying rare disorders, including
the researchers at IHG PAS."
With the SOPHiA DDM™ Platform, IHG PAS will retain complete
ownership of its database, supporting its research team as it
continues to increase its expertise and build upon its
learnings.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect on X,
LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
1
https://www.who.int/news/item/04-04-2023-1-in-6-people-globally-affected-by-infertility
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-institute-of-human-genetics-polish-academy-of-sciences-ihg-pas-is-live-on-sophia-genetics-301992098.html
SOURCE SOPHiA GENETICS